Results from randomized placebo-controlled trials have demonstrated that in subjects with T2DM and atherosclerotic cardiovascular disease, both SGLT2 inhibitors and GLP1-RAs showed proven cardiovascular benefits, including reduced hospitalization and mortality risk. The gene discussed is GCG; the disease is type 2 diabetes mellitus.